Compare Neurocrine Biosciences Inc (NBIX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Verisign, Inc. — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Verisign, Inc. trades at $277.5 (market cap $25.26B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.17% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | VRSN | |
|---|---|---|
Market Cap | $17.40B | $25.26B |
Sector | Health | Technology |
52-Week High | $180.55 | $310.00 |
52-Week Low | $123.10 | $211.49 |
Enterprise Value | $16.49B | $26.50B |
Dividend Yield | — | 1.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
